Document:

Exhibit
10.5

 

EMPLOYMENT AGREEMENT

 

AGREEMENT dated as of June 18,
2021 between Ilya Rachman, (“Executive”), and Immix Biopharma, Inc., a Delaware corporation having its principal office at
10573 W. Pico Blvd., # 58, Los Angeles, CA 90064 (“Company”);

 

WHEREAS, the Company desires to
employ Executive, and Executive desires to be employed by the Company, on the terms and conditions herein set forth;

 

IT IS AGREED:

 

1. Employment, Duties and Acceptance.

 

1.1 General. The Company
hereby agrees to employ the Executive as its Chief Executive Officer. All of Executive’s powers and authority in any capacity shall
at all times be subject to the direction and control of the Company’s Board of Directors (“Board”). The Board may assign
to Executive such management and supervisory responsibilities and executive duties for the Company or any subsidiary of the Company, including
serving as an executive officer and/or director of any subsidiary, as are consistent with Executive’s status as Chief Executive
Officer. The Company and Executive acknowledge that Executive’s primary functions and duties as Chief Executive Officer shall be
general management and control of the affairs and business of the Company.

 

1.2 Duties. Executive accepts
such employment and agrees to devote such time as he reasonably deems necessary to the performance of his duties hereunder. Nothing herein
shall be construed as preventing Executive from (i) making and supervising investments on a personal or family basis (including trusts,
funds and investment entities in which Executive or members of his family have an interest) and (ii) in serving as a consultant to, or
on boards of directors of, or in any other capacity to other companies, for profit and not for profit, provided they will not interfere
with the performance of Executive’s duties hereunder or violate the provisions of Section 5.4 hereof.

 

1.3 Location. Executive will
perform his duties in California. Executive shall undertake such occasional travel, within or outside the United States, as is reasonably
necessary in the interests of the Company.

 

2. Term. The term of Executive’s
employment hereunder shall commence on June 18 2021 and terminate on June 18 2024 (“Term”) unless terminated earlier as hereinafter
provided in this Agreement, or unless extended by mutual written agreement of the Company and Executive. Unless the Company and Executive
have otherwise agreed in writing, if Executive continues to work for the Company after the expiration of the Term, his employment thereafter
shall be under the same terms and conditions provided for in this Agreement, except that his employment will be on an “at will”
basis and the provisions of Sections 4.4 and 4.6(c) shall no longer be in effect.

 

3. Compensation and Benefits.

 

3.1 Salary. The Company shall
pay to Executive a salary (“Base Salary”) at the annual rate of $360,000. Executive’s compensation shall be paid in
equal, periodic installments in accordance with the Company’s normal payroll procedures; provided however, that Executive’s
Base Salary shall be accrued and deferred until such time as the Company consummates a “Qualified Financing” as defined in
that such Convertible Promissory Note issued by the Company to Mesa Verde Venture Partners III, LP (dated October 30, 2019), at which
time such accrued and deferred Base Salary shall be paid to Executive in full.

 

    	 	1	 

    	 

    

 

3.2 Bonus. In addition to
the Base Salary, Executive shall be paid a bonus (“Bonus”) on January 1st of each year beginning in 2022 equal
to 100% of the Base Salary plus additional performance bonuses to be determined by the Board. The Bonus shall be contingent upon the Company
meeting annual performance objectives, which shall be established annually at the first meeting each fiscal year by the Board of Directors.
For the avoidance of doubt, whether Executive receives an annual bonus for any given year will be determined by the Board in its sole
discretion.

 

3.3 Stock Options. The Board (or Compensation
Committee) may, in its sole discretion, grant Employee options to purchase shares of the Company’s common stock from time to time
under the Company’s equity compensation plans, but Executive understands that it is under no obligation to do so.

 

3.4 Benefits. Executive shall
be entitled to such medical, life, disability and other benefits as are generally afforded to other executives of the Company, subject
to applicable waiting periods and other conditions, as well as participation in all other company-wide employee benefits, including a
defined contribution pension plan and 401(k) plan, as may be made available generally to executive employees from time to time.

 

3.5 Vacation and Sick Days.
Executive shall be entitled to twenty-five (25) days of paid vacation and five (5) days of paid sick days in each year during the Term
and to a reasonable number of other days off for religious and personal reasons in accordance with customary Company policy.

 

3.6 Expenses. The Company
shall pay or reimburse Executive for all transportation, hotel and other expenses reasonably incurred by Executive on business trips and
for all other ordinary and reasonable out-of-pocket expenses actually incurred by him in the conduct of the business of the Company, including
expenses relating to his laptop, cell phone and Blackberry or other similar devices, against itemized vouchers submitted with respect
to any such expenses and approved in accordance with customary procedures.

 

4. Termination.

 

4.1 Death. If Executive dies
during the Term, Executive’s employment hereunder shall terminate and the Company shall pay to Executive’s estate the amount
set forth in Section 4.6(a).

 

4.2 Disability. The Company,
by written notice to Executive, may terminate Executive’s employment hereunder if Executive shall fail because of illness or incapacity
to render services of the character contemplated by this Agreement for one hundred eighty (180) days. Upon such termination, the Company
shall pay to Executive the amount set forth in Section 4.6(a).

 

4.3 By Company for “Cause”.
The Company, by written notice to Executive, may terminate Executive’s employment hereunder for “Cause”. As used herein,
“Cause” shall mean: (a) the refusal or failure by Executive to carry out specific directions of the Board which are of a material
nature and consistent with his status as Chief Executive Officer (or whichever positions Executive holds at such time), or the refusal
or failure by Executive to perform a material part of Executive’s duties hereunder; (b) the commission by Executive of a material
breach of any of the provisions of this Agreement; (c) gross negligence or willful misconduct by Executive in his relations with the Company
or any of its subsidiaries or affiliates; or (d) the conviction of Executive of a felony under federal or state law. Notwithstanding the
foregoing, no “Cause” for termination shall be deemed to exist with respect to Executive’s acts described in clauses
(a) or (b) above, unless the Company shall have given written notice to Executive within a period not to exceed ten (10) calendar days
of the initial existence of the occurrence, specifying the “Cause” with reasonable particularity and, within thirty (30) calendar
days after such notice, Executive shall not have cured or eliminated the problem or thing giving rise to such “Cause;” provided,
however, no more than two cure periods need be provided during any twelve-month period. Upon such termination, the Company shall pay to
Executive the amount set forth in Section 4.6(b).

 

    	 	2	 

    	 

    

 

4.4 By Executive for “Good
Reason”. The Executive, by written notice to the Company, may terminate Executive’s employment hereunder if a “Good
Reason” exists. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following circumstances
without the Executive’s prior written consent: (a) a substantial and material adverse change in the nature of Executive’s
title, duties or responsibilities with the Company that represents a demotion from his title, duties or responsibilities as in effect
immediately prior to such change (such change, a “Demotion”); (b) material breach of this Agreement by the Company; (c) a
failure by the Company to make any payment to Executive when due, unless the payment is not material and is being contested by the Company,
in good faith; or (d) a liquidation, bankruptcy or receivership of the Company. Notwithstanding the foregoing, no “Good Reason”
shall be deemed to exist with respect to the Company’s acts described in clauses (a), (b) or (c) above, unless Executive shall have
given written notice to the Company within a period not to exceed ten (10) calendar days of the initial existence of the occurrence, specifying
the “Good Reason” with reasonable particularity and, within thirty (30) calendar days after such notice, the Company shall
not have cured or eliminated the problem or thing giving rise to such “Good Reason”; provided, however, that no more than
two cure periods shall be provided during any twelve-month period of a breach of clauses (a), (b) or (c) above. Upon such termination,
the Company shall pay to Executive the amount set forth in Section 4.6(c).

 

4.5 By Company Without “Cause”.
The Company may terminate Executive’s employment hereunder without “Cause” by giving at least one hundred eighty (180)
days written notice to Executive. Upon such termination, the Company shall pay to Executive the amount set forth in Section 4.6(c).

 

4.6 Compensation Upon Termination.
In the event that Executive’s employment hereunder is terminated, the Company shall pay to Executive the following compensation:

 

(a) Payment Upon Death or Disability.
In the event that Executive’s employment is terminated pursuant to Sections 4.1 or 4.2, the Company shall no longer be under any
obligation to Executive or his legal representatives pursuant to this Agreement except for: (i) the Base Salary due Executive pursuant
to Section 3.1 hereof through the date of termination; (ii) any Bonus which would have become payable under Section 3.2 for the year in
which the employment was terminated prorated by multiplying the full amount of the Bonus by a fraction, the numerator of which is the
number of “full calendar months” worked by Executive during the year of termination and the denominator of which is 12 (a
“full calendar month” is a month in which the Executive worked at least two weeks); (iii) all earned and previously approved
but unpaid Bonuses for any year prior to the year of termination; (iv) all valid expense reimbursements, and (v) all accrued but unused
vacation pay.

 

(b) Payment Upon Termination
by the Company For “Cause”. In the event that the Company terminates Executive’s employment hereunder pursuant to
Section 4.3, the Company shall have no further obligations to the Executive hereunder, except for: (i) the Base Salary due Executive pursuant
to Section 3.1 hereof through the date of termination (ii) all valid expense reimbursements and (ii) all unused vacation pay through the
date of termination required by law to be paid.

 

(c) Payment Upon Termination
by Company Without Cause or by Executive for Good Reason. In the event that Executive’s employment is terminated pursuant to
Sections 4.4 or 4.5, the Company shall have no further obligations to Executive hereunder except for: (i) 150% of the Base Salary due
Executive pursuant to Section 3.1 hereof through the end of the Term, payable in full; (ii) all valid expense reimbursements; and (iii)
all accrued but unused vacation pay.

 

(d) Executive shall
have no duty to mitigate awards paid or payable to him pursuant to this Agreement, and any compensation paid or payable to Executive from
sources other than the Company will not offset or terminate the Company’s obligation to pay to Executive the full amounts pursuant
to this Agreement.

 

    	 	3	 

    	 

    

 

5. Protection of Confidential Information; Non-Competition.

 

5.1 Acknowledgment. Executive acknowledges that:

 

(a) As a result of his current
and prior employment with the Company, Executive has obtained and will obtain secret and confidential information concerning the business
of the Company and its subsidiaries (referred to collectively in this Section 5 as the “Company”), including, without limitation,
financial information, proprietary rights, trade secrets and “know-how,” customers and sources (“Confidential Information”).

 

(b) The Company will suffer substantial
damage which will be difficult to compute if, during the period of his employment with the Company or thereafter, Executive should enter
a business competitive with the Company or divulge Confidential Information.

 

(c) The provisions of this Agreement
are reasonable and necessary for the protection of the business of the Company.

 

5.2 Confidentiality. Executive
agrees that he will not at any time, during the Term or thereafter, divulge to any person or entity any Confidential Information obtained
or learned by him as a result of his employment with the Company, except (i) in the course of performing his duties hereunder, (ii) with
the Company’s prior written consent; (iii) to the extent that any such information is in the public domain other than as a result
of Executive’s breach of any of his obligations hereunder; or (iv) where required to be disclosed by law, regulation, stock exchange
rule, court order, subpoena or other government process. If Executive shall be required to make disclosure pursuant to the provisions
of clause (iv) of the preceding sentence, Executive promptly, but in no event more than 48 hours after learning of such subpoena, court
order, or other government process, shall notify, confirmed by mail, the Company and, at the Company’s expense, Executive shall:
(a) take all reasonably necessary and lawful steps required by the Company to defend against the enforcement of such subpoena, court order
or other government process, and (b) permit the Company to intervene and participate with counsel of its choice in any proceeding relating
to the enforcement thereof.

 

5.3 Documents. Upon termination
of his employment with the Company, Executive will promptly deliver to the Company all memoranda, notes, records, reports, manuals, drawings,
blueprints and other documents (and all copies thereof) relating to the business of the Company and all property associated therewith,
which he may then possess or have under his control; provided, however, that Executive shall be entitled to retain copies of such documents
reasonably necessary to document his financial relationship with the Company.

 

5.4 Non-competition. During
the Term and for a period of six (6) months thereafter, Executive, without the prior written permission of the Company, shall not, anywhere
in the world, (i) be employed by, or render any services to, any person, firm or corporation engaged in the biopharmaceutical industry
or any other business which is directly in competition with any “material” business conducted by the Company or any of its
subsidiaries at the time of termination (as used herein “material” means a business which generated at least 10% of the Company’s
consolidated revenues for the last full fiscal year for which audited financial statements are available) (“Competitive Business”);
(ii) engage in any Competitive Business for his or its own account; (iii) be associated with or interested in any Competitive Business
as an individual, partner, shareholder, creditor, director, officer, principal, agent, employee, trustee, consultant, advisor or in any
other relationship or capacity; (iv) employ or retain, or have or cause any other person or entity to employ or retain, any person who
was employed or retained by the Company while Executive was employed by the Company (other than Executive’s personal secretary and
assistant); or (v) solicit, interfere with, or endeavor to entice away from the Company, for the benefit of a Competitive Business, any
of its customers or other persons with whom the Company has a contractual relationship. Notwithstanding the foregoing, nothing in this
Agreement shall preclude Executive from investing his personal assets in any manner he chooses, provided, however, that Executive may
not, during the period referred to in this Section 5.4, own more than 4.9% of the equity securities of any Competitive Business.

 

    	 	4	 

    	 

    

 

5.5 Injunctive Relief. If
Executive commits a breach, or threatens to commit a breach, of any of the provisions of Sections 5.2 or 5.4, the Company shall have the
right and remedy to seek to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being
acknowledged and agreed by Executive that the services being rendered hereunder to the Company are of a special, unique and extraordinary
character and that any such breach or threatened breach will cause irreparable injury to the Company and that money damages will not provide
an adequate remedy to the Company. The rights and remedies enumerated in this Section 5.5 shall be in addition to, and not in lieu of,
any other rights and remedies available to the Company under law or equity. In connection with any legal action or proceeding arising
out of or relating to this Agreement, the prevailing party in such action or proceeding shall be entitled to be reimbursed by the other
party for the reasonable attorneys’ fees and costs incurred by the prevailing party.

 

5.6 Modification. If any
provision of Sections 5.2 or 5.4 is held to be unenforceable because of the scope, duration or area of its applicability, the tribunal
making such determination shall have the power to modify such scope, duration, or area, or all of them, and such provision or provisions
shall then be applicable in such modified form.

 

5.7 Survival. The provisions
of this Section 5 shall survive the termination of this Agreement for any reason, except in the event Executive is terminated by the Company
without “Cause,” or if Executive terminates this Agreement with “Good Reason,” in either of which events, clauses
(i), (ii) and (iii) of Section 5.4 shall be null and void and of no further force or effect. The non-renewal of this Agreement at the
end of the Term shall not be a termination by the Company without “Cause”.

 

6. Miscellaneous Provisions.

 

6.1 Notices. All notices
provided for in this Agreement shall be in writing, and shall be deemed to have been duly given when (i) delivered personally to the party
to receive the same, or (ii) when mailed first class postage prepaid, by certified mail, return receipt requested, addressed to the party
to receive the same at his or its address set forth below, or such other address as the party to receive the same shall have specified
by written notice given in the manner provided for in this Section 6.1. All notices shall be deemed to have been given as of the date
of personal delivery or mailing thereof.

 

If to Executive:

Ilya Rachman

ilya.rachman@immixbio.com

 

If to the Company:

Immix Biopharma, Inc.

10573 W. Pico Blvd., # 58, Los Angeles, CA
90064

legal@immixbio.com

 

6.2 Entire Agreement; Waiver.
This Agreement sets forth the entire agreement of the parties relating to the employment of Executive and is intended to supersede all
prior negotiations, understandings and agreements. No provisions of this Agreement may be waived or changed except by a writing by the
party against whom such waiver or change is sought to be enforced. The failure of any party to require performance of any provision hereof
or thereof shall in no manner affect the right at a later time to enforce such provision.

 

    	 	5	 

    	 

    

 

6.3 Governing Law. All questions
with respect to the construction of this Agreement, and the rights and obligations of the parties hereunder, shall be determined in accordance
with the law of the State of California applicable to agreements made and to be performed entirely in California.

 

6.4 Binding Effect; Nonassignability.
This Agreement shall inure to the benefit of and be binding upon the successors and assigns of the Company. This Agreement shall not be
assignable by Executive, but shall inure to the benefit of and be binding upon Executive’s heirs and legal representatives.

 

6.5 Severability. Should
any provision of this Agreement become legally unenforceable, no other provision of this Agreement shall be affected, and this Agreement
shall continue as if the Agreement had been executed absent the unenforceable provision.

 

6.6 Section 409A. This Agreement
is intended to comply with the provisions of Section 409A of the Internal Revenue Code (“Section 409A”). To the extent that
any payments and/or benefits provided hereunder are not considered compliant with Section 409A, the parties agree that the Company shall
take all actions necessary to make such payments and/or benefits become compliant.

 

6.7 Ownership of Work Product.
Executive hereby irrevocably assigns to the Company all right, title and interest worldwide in and to any ideas, concepts, processes,
discoveries, developments, formulae, information, materials, improvements, designs, artwork, content, software programs, other copyrightable
works, and any other work product created, conceived or developed by Executive (whether alone or jointly with others) for the Company
during or before the term of this Agreement, including all copyrights, patents, trademarks, trade secrets, and other intellectual property
rights therein (collectively, the “Work Product”). Executive retain no rights to use the Work Product and agree not to challenge
the validity of the Company’s ownership of the Work Product. Executive agrees to execute, at the Company’s request and expense,
all documents and other instruments necessary or desirable to confirm such assignment, including without limitation, any copyright assignment
or patent assignment provided by the Company. Executive hereby irrevocably appoints Company as their attorney-in-fact for the purpose
of executing such documents on their respective behalf, which appointment is coupled with an interest. At Company’s request, Executive
will promptly record any such patent assignment with the United States Patent and Trademark Office. Company will Executive for any reasonable
out-of-pocket expenses actually incurred by Executive in fulfilling his obligations under this section.

 

    	 	6	 

    	 

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement on the date first above written.

 

	 	IMMIX BIOPHARMA, INC.
	 	 
	 	/s/
    Ilya Rachman
	 	 
	 	Ilya Rachman
	 	 
	 	/s/
    Ilya Rachman 

 

    	 	7Exhibit
10.6

 

MANAGEMENT
SERVICES AGREEMENT

 

This
MANAGEMENT SERVICES AGREEMENT (“Agreement”) is made and entered into as of the 24th day of March, 2021
by and between Alwaysraise, LLC, a California limited liability company (“Alwaysraise”), and Immix Biopharma Inc., a Delaware
corporation (“Company”) each a “party” and collectively the “parties”.

 

WHEREAS,
Gabriel Morris (“Mr. Morris”) is the sole principal of Alwaysraise; and

 

WHEREAS,
the Company desires that Alwaysraise make Mr. Morris available to the Company to serve, in accordance with the Company’s bylaws,
as the Company’s chief financial officer.

 

NOW,
therefore, it is agreed as follows:

 

1.
Chief Financial Officer Appointment. Alwaysraise, in accordance with the provisions of this Agreement, shall make Mr. Morris available
to serve as chief financial officer of the Company and any of the Company’s subsidiaries. Mr. Morris shall be granted the corporate
power, authorities and responsibilities of a chief financial officer and he shall perform and provide all services that are customarily
provided by a chief financial officer.

 

2.
Board of Directors Supervision. The activities of Mr. Morris to be performed under this Agreement as chief financial officer shall
be subject to the supervision and decisions of the Board of Directors of the Company (the “Board”) to the extent required
by applicable law, bylaws, articles, resolutions, regulations and reasonable policies not inconsistent with the terms of this Agreement
adopted by the Board and in effect from time to time.

 

3.
No Further Authority of Alwaysraise. Alwaysraise shall provide no additional services or have any right to provide services for
the benefit of the Company absent the approval of the Company’s Board.

 

4.
Compensation. For the services Mr. Morris performs hereunder, the Company shall pay to Alwaysraise a monthly management services
fee of $10,000 payable in arrears from the signing of this agreement through November 2021. Beginning in December, 2021 and for all months
thereafter, the Company shall pay to Alwaysraise a monthly management services fee of $20,000, payable in arrears. Additionally, the
Company agrees that Mr. Morris shall be eligible, based on performance and subject to approval of the Equity Incentive Plan(s) by the
Board, to receive option grants that are reasonably and customarily granted to a chief financial officer of a company of such size and
industry, pursuant to the Immix Biopharma, Inc. 2016 Equity Incentive Plan passed by Board resolution on November 30,2016 and the Immix
Biopharma, Inc. 2016 Option Agreement passed by Board resolution on November 30,2016 and/or further plans to be approved by the Board.

 

5.
Ownership of Work Product. Alwaysraise and Mr. Morris both hereby irrevocably assign to the Company all right, title and interest
worldwide in and to any ideas, concepts, processes, discoveries, developments, formulae, information, materials, improvements, designs,
artwork, content, software programs, other copyrightable works, and any other work product created, conceived or developed by Alwaysraise
or Mr. Morris (whether alone or jointly with others) for the Company during or before the term of this Agreement, including all copyrights,
patents, trademarks, trade secrets, and other intellectual property rights therein (collectively, the “Work Product”). Alwaysraise
and Mr. Morris both retain no rights to use the Work Product and agree not to challenge the validity of the Company’s ownership
of the Work Product. Alwaysraise and Mr. Morris agree to execute, at the Company’s request and expense, all documents and other
instruments necessary or desirable to confirm such assignment, including without limitation, any copyright assignment or patent assignment
provided by the Company. Alwaysraise and Mr. Morris each hereby irrevocably appoint Company as their attorney-in-fact for the purpose
of executing such documents on their respective behalf, which appointment is coupled with an interest. At Company’s request, Alwaysraise
and/or Mr. Morris will promptly record any such patent assignment with the United States Patent and Trademark Office. Company will reimburse
Alwaysraise and/or Mr. Morris for any reasonable out-of-pocket expenses actually incurred by Alwaysraise or Mr. Morris in fulfilling
its obligations under this section.

 

    	Page 1

    	 

    

 

6. Other
Rights. If Alwaysraise and/or Mr. Morris have any rights, including without limitation “artist’s rights” or
“moral rights,” in the Work Product that cannot be assigned, Alwaysraise and Mr. Morris each hereby unconditionally and
irrevocably grant to Company an exclusive (even as to Alwaysraise and Mr. Morris), worldwide, fully paid and royalty-free,
irrevocable, perpetual license, with rights to sublicense through multiple tiers of sublicensees, to use, reproduce, distribute,
create derivative works of, publicly perform and publicly display the Work Product in any medium or format, whether now known or
later developed. In the event that Alwaysraise and/or Mr. Morris have any rights in the Work Product that cannot be assigned or
licensed, they each unconditionally and irrevocably waive the enforcement of such rights, and all claims and causes of action of any
kind against Company or Company’s customers.

 

7.
Reimbursement of Expenses. All obligations or expenses incurred by Alwaysraise in the performance of Mr. Morris’s duties
under this Agreement shall be for the account of, on behalf of, and at the expense of the Company. Alwaysraise shall not be obligated
to make any advance to or for the account of the Company or to pay any sums, except out of funds held in accounts maintained by the Company
nor shall Alwaysraise be obligated to incur any liability or obligation for the account of the Company without assurance that the necessary
funds for the discharge of such liability or obligation will be provided.

 

8.
Time and Attention. Alwaysraise shall cause Mr. Morris to give the time and attention to his duties hereunder that are reasonably
required to perform the services required of him hereunder.

 

9. Confidential
Information. During the term of this Agreement and thereafter Alwaysraise and Mr. Morris (i) will not use or permit the use of
Company’s Confidential Information in any manner or for any purpose not expressly set forth in this Agreement, (ii) will hold
such Confidential Information in confidence and protect it from unauthorized use and disclosure, and (iii) will not disclose such
Confidential Information to any third parties except as set forth in this section. Alwaysraise and Mr. Morris will protect
Company’s Confidential Information from unauthorized use, access or disclosure in the same manner as Alwaysraise and Mr.
Morris protect their own confidential information of a similar nature, but in no event will it exercise less than reasonable care.
Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Company and Alwaysraise
and Mr. Morris, nothing in this Agreement shall limit Alwaysraise’s or Mr. Morris’ right to report possible violations
of law or regulation with any federal, state, or local government agency. “Confidential Information” as used in this
Agreement means all information disclosed by Company to Alwaysraise and/or Mr. Morris, whether during or before the term of this
Agreement, that is not generally known in the Company’s trade or industry and will include, without limitation: (a) concepts
and ideas relating to the development and distribution of content in any medium or to the current, future and proposed products or
services of Company or its subsidiaries or affiliates; (b) trade secrets, drawings, inventions, know-how, software programs, and
software source documents; (c) information regarding plans for research, development, new service offerings or products, marketing
and selling, business plans, business forecasts, budgets and unpublished financial statements, licenses and distribution
arrangements, prices and costs, suppliers and customers; (d) existence of any business discussions, negotiations or agreements
between the parties; and (e) any information regarding the skills and compensation of employees, contractors or other agents of
Company or its subsidiaries or affiliates. Confidential Information also includes proprietary or confidential information of any
third party who may disclose such information to Company or Alwaysraise or Mr. Morris in the course of Company’s business.
Confidential Information does not include information that (x) is or becomes a part of the public domain through no act or omission
of Alwaysraise or Mr. Morris, (y) is disclosed to Alwaysraise or Mr. Morris by a third party without restrictions on disclosure, or
(z) was in Alwaysraise’s or Mr. Morris’ lawful possession without obligation of confidentiality prior to the disclosure
and was not obtained by Alwaysraise or Mr. Morris either directly or indirectly from Company. In addition, this section will not be
construed to prohibit disclosure of Confidential Information to the extent that such disclosure is required by law or valid order of
a court or other governmental authority; provided, however, that Alwaysraise and/or Mr. Morris will first have given notice to
Company and will have made a reasonable effort to obtain a protective order requiring that the Confidential Information so disclosed
be used only for the purposes for which the order was issued. All Confidential Information furnished to Alwaysraise and/or Mr.
Morris by Company is the sole and exclusive property of Company or its suppliers or customers. Upon request by Company, Alwaysraise
and/or Mr. Morris agree to promptly deliver to Company the original and any copies of the Confidential Information. Notwithstanding
the foregoing nondisclosure obligations, pursuant to 18 U.S.C. Section 1833(b), Alwaysraise and Mr. Morris will not be held
criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (1) in
confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the
purpose of reporting or investigating a suspected violation of law; or (2) in a complaint or other document filed in a lawsuit or
other proceeding, if such filing is made under seal.

 

    	Page 2

    	 

    

 

10.
Term and Termination. This Agreement shall remain in effect for a period of two years (“Initial Term”) and thereafter,
shall be automatically renewed for successive one year terms (each an “Extension Term”) unless, either party prior to the
end of the Initial Term or any Extension Term terminates this Agreement by delivering a written termination notice 60 days in advance
of the proposed termination date. If the Company delivers the termination notice, the Agreement will terminate on the termination date,
and the Company shall, pay the monthly management service fees and expenses accrued hereunder and for all remaining months of the then
applicable term in which such termination occurred in a single lump-sum payment, payable in full prior to the termination date. If Alwaysraise
delivers the termination notice, the Agreement will terminate on the termination date, and the Company shall pay monthly management service
fees and expenses which have accrued prior to the termination date in a single lump-sum payment, payable in full prior to the termination
date. Notwithstanding the termination of this Agreement, Sections 12, 14 and 18 shall survive such termination. Notwithstanding anything
to the contrary in this Section 10, or elsewhere, in this Agreement the Company shall have the right, upon 30 days prior written notification
to Alwaysraise, to terminate this Agreement without liability at any time during the Initial Term or any Extension Term for Cause (as
defined in that certain writing entitled “2016 Equity Incentive Plan” dated and passed by Board resolution on November 30,
2016), or failure of Alwaysraise to comply with the terms or conditions of this Agreement.

 

11.
Standard of Care. Alwaysraise and Mr. Morris shall not be liable for any mistakes of fact, errors of judgment, for losses sustained
by the Company or for any acts or omissions of any kind (including acts or omissions of Alwaysraise), unless the Company’s losses
(including expenses, costs and attorneys’ fees) are finally and judicially determined to have resulted from the gross negligence
or willful misconduct of Alwaysraise.

 

12.
Indemnification. The Company agrees to indemnify and hold harmless Alwaysraise and Mr. Morris from and against any and all losses,
claims, damages or liabilities, including reasonable attorney’s fees (collectively “Losses”) suffered or incurred
by Alwaysraise or Mr. Morris in connection with the provision of services under this Agreement (except to the extent such Losses result
from the gross negligence of or willful misconduct of Mr. Morris in performing services hereunder); provided, that such indemnity shall
be limited to the total amount of fees actually paid to Alwaysraise pursuant to this Agreement.. Alwaysraise agrees to indemnify the
Company for Losses incurred as a result of the gross negligence or willful misconduct of Alwaysraise or Mr. Morris in providing services
hereunder ; provided, that such indemnity shall be limited to the total amount of fees actually paid to Alwaysraise pursuant to this
Agreement.

 

    	Page 3

    	 

    

 

13.
No Assignment. Without the consent of either party hereto, neither party shall assign, transfer or convey any of its rights, duties
or interest under this Agreement, nor shall it delegate any of the obligations or duties required to be kept or performed by it hereunder.

 

14.
Notices. All notices, demands, consents, approvals and requests given by either party to the other hereunder shall be in writing
and shall be personally delivered or sent by registered or certified mail, return receipt requested, postage prepaid, to the parties
at the following addresses, or upon actual receipt if given by electronic mail and such receipt is confirmed in writing by the recipient:

 

	 	If
    to the Company:	Immix
                                            Biopharma, Inc.

    10573
    W Pico Blvd #58

    Los
    Angeles, CA 90064

    Attention:
    Ilya Rachman, MD, PhD

    Email:
    ilya.rachman@immixbio.com

 

	 	If
    to Alwaysraise:	Alwaysraise
                                            LLC

    1592
    Union Street #4000

    San
    Francisco, CA, 94123

    Attention:
    Gabriel Morris

    Email:
notices@alwaysraise.com

 

Any
party may at any time change its respective address by sending written notice to the other party of the change in the manner hereinabove
prescribed.

 

15.
Severability. If any term or provision of this Agreement or the application thereof to any person or circumstance shall, to any
extent, be invalid or unenforceable, the remainder of this Agreement, or the application of such term or provision to persons or circumstances
other than those as to which it is held invalid or enforceable, shall not be affected thereby, and each term and provision of this Agreement
shall be valid and be enforced to the fullest extent permitted by law.

 

16.
No Waiver. The failure by any party to exercise any right, remedy or elections herein contained or permitted by law shall not
constitute or be construed as a waiver or relinquishment for the future exercise of such right, remedy or election, but the same shall
continue and remain in full force and effect. All rights and remedies that any party may have at law, in equity or otherwise upon breach
of any term or condition of this Agreement, shall be distinct, separate and cumulative rights and remedies and no one of them, whether
exercised or not, shall be deemed to be in exclusion of any other right or remedy.

 

17.
Entire Agreement. This Agreement contains the entire agreement between the parties hereto with respect to the matters herein contained
and any agreement hereafter made shall be ineffective to effect any change or modification, in whole or in part, unless such agreement
is in writing and signed by the party against whom enforcement of the change or modification is sought.

 

18.
Governing Laws. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law.

 

    	Page 4

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly as of the date first above written.

 

	 	IMMIX
    BIOPHARMA, INC.
	 	 	 
	 	By:	/s/
    Ilya Rachman, MD
	 	Name:	 
	 	Title:	 
	 	 	 
	 	ALWAYSRAISE
    LLC
	 	 	 
	 	By:	/s/
    Gabriel Morris
	 	Name:	Gabriel
    Morris

 

	ACKNOWLEDGED
    AND ACCEPTED:	 
	 	 
	/s/
    Gabriel Morris	 
	Gabriel
Morris	 

 

    	Page 5

    	 

    

 

RE:
Management Services Agreement – Addendum A

June
18, 2021

 

Further
to the Management Services Agreement dated March 24, 2021 (the “Agreement”) by and between Immix Biopharma, Inc. (the
“Company”) and Alwaysraise LLC (“Alwaysraise”), this letter (“Addendum A”) hereby adds
the new Section 19 below to the Agreement and amends Section 10:

 

“19.
Additional Provisions.

 

	 	(a)	Bonus.
    In addition to compensation in Section 4, Mr. Morris shall be paid a bonus (“Bonus”) on January 1st of each
    year beginning in 2022 equal to 100% of the most recent 12 month compensation as referenced in Section 4 hereof plus additional performance
    bonuses to be determined by the Board. The Bonus shall be contingent upon the Company meeting annual performance objectives, which
    shall be established annually at the first meeting each fiscal year by the Board of Directors. For the avoidance of doubt, whether
    Mr. Morris receives an annual bonus for any given year will be determined by the Board in its sole discretion.
	 	 	 
	 	(b)	Benefits.
    Mr. Morris shall be entitled to such medical, life, disability and other benefits as are generally afforded to other executives of
    the Company, subject to applicable waiting periods and other conditions, as well as participation in all other company-wide employee
    benefits, including a defined contribution pension plan and 401(k) plan, as may be made available generally to executive employees
    from time to time. 
	 	 	 
	 	(c)	Vacation
    and Sick Days. Mr. Morris shall be entitled to twenty-five (25) days of paid vacation and five (5) days of paid sick days in
    each year during the Term and to a reasonable number of other days off for religious and personal reasons in accordance with customary
    Company policy.
	 	 	 
	 	(d)	Death.
    If Mr. Morris dies during the Term, the Agreement shall terminate and the Company shall pay to Mr. Morris’s estate the amount
    set forth in Section 10.
	 	 	 
	 	(e)	Disability.
    The Company, by written notice to Mr. Morris, may terminate the Agreement if Mr. Morris shall fail because of illness or incapacity
    to render services of the character contemplated by this Agreement for one hundred eighty (180) days. Upon such termination, the
    Company shall pay to Mr. Morris the amount set forth in Section 10.
	 	 	 
	 	(f)	No
    Mitigation. Mr. Morris shall have no duty to mitigate awards paid or payable to him pursuant to this Agreement, and any compensation
    paid or payable to Mr. Morris from sources other than the Company will not offset or terminate the Company’s obligation to
    pay to Mr. Morris the full amounts pursuant to this Agreement. “

 

The
parties hereby amend Section 10 “Term and Termination” specifically as follows, and not otherwise:

 

	 	1.	1st
    Sentence: Delete the words “two years” and insert the words “three years,” after the words “period
    of” such that the “Initial Term” is changed from two (2) years to three (3) years and otherwise the first sentence
    is unchanged.
	 	 	 
	 	2.	2nd
    Sentence: Insert the words “one hundred fifty percent (150%) of” in front of the words “the monthly management
    service fees” and otherwise the second sentence is unchanged.
	 	 	 
	 	3.	5th
    Sentence: Delete “Notwithstanding anything to the contrary in this Section 10, or elsewhere,” and otherwise
    the fifth sentence is unchanged.
	 	 	 
	 	4.	Added
    Sentences. The following sentences are added to end of Section 10: “Notwithstanding anything to the contrary in this Section
    10, or elsewhere, no “Cause” for termination shall be deemed to exist with respect to Alwaysraise or Mr. Morris as described
    in this clause 10 “Term and Termination”, unless the Company shall have given written notice to Alwaysraise and Mr. Morris
    within a period not to exceed ten (10) calendar days after the initial existence of the occurrence, specifying the basis for “Cause”
    with reasonable particularity and, within thirty (30) calendar days after such notice, Alwaysraise or Mr. Morris shall not have cured
    or eliminated the basis for “Cause;” provided, however, no more than two cure periods need be provided during any twelve-month
    period. Upon such termination, the Company shall pay the amount due under this Section 10. The parties agree that (a) the Company
    may terminate this Agreement hereunder without “Cause” by giving at least one hundred eighty (180) days written notice
    to Alwaysraise; and (b) if a substantial and material adverse change in the nature of Mr. Morris’ title, duties or responsibilities
    with the Company (a “Demotion”) takes place, the Company shall terminate this Agreement immediately upon delivery of
    a written notice from Alwaysraise or Mr. Morris (a “Demotion Notice”). Upon such termination per clause (a) or (b) in
    the immediately preceding sentence, the Company agrees that no “Cause” for termination will be deemed to exist with respect
    any such termination and the Company agrees to pay the amount due under this Section 10 in the circumstances under which no Cause
    for termination exists.” 

 

    	Page 6

    	 

    

 

All
other terms and conditions of the Agreement remain in place.

 

	IMMIX BIOPHARMA, INC.

	 	ALWAYSRAISE LLC 

	 	 	 
	By:	/s/
    Ilya Rachman 	 	By:	/s/
    Gabriel Morris
	Name:	Ilya
    Rachman	 	Name:	Gabriel
    Morris
	Title:	CEO,
    Immix Biopharma	 	Title:	 

 

	ACKNOWLEDGED
    AND ACCEPTED:	 
	 	 
	/s/
    Gabriel Morris	 
	Gabriel
    Morris	 

 

    	Page 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]